Quick Answer
enGene Therapeutics Inc. reported Operating Income Loss of -$123.17 million for the year ending 2025.
- enGene Therapeutics Inc. showed a decrease of -97.7% in Operating Income Loss from 2024 to 2025.
- This data is from enGene Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on December 22, 2025.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$4.63 million | Q2 2023: -$4.74 million | Q3 2023: -$6.25 million | Q1 2024: -$10.77 million | Q2 2024: -$17.31 million | Q3 2024: -$16.76 million | Q1 2025: -$26.61 million | Q2 2025: -$27.12 million | Q3 2025: -$29.95 million | Q1 2026: -$31.19 million.
- Over the full 4 years of available data (2022 to 2025), enGene Therapeutics Inc.'s Operating Income Loss has declined by 534.0%.
- Historical annual values: Fiscal year 2025: -$123.17 million | Fiscal year 2024: -$62.30 million | Fiscal year 2023: -$26.06 million | Fiscal year 2022: -$19.43 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: